Bon Natural Life Limited

For fiscal year 2022, Bon Natural Life reported revenue of approximately $29.9 million, up 17.3% year over year. Gross profit was approximately $9.4 million, up 32.5%, net income increased to about $6.2 million from $4.6 million, and diluted EPS was $0.74 versus $0.68 in fiscal 2021. By segment, fragrance compounds revenue rose 7.6% to about $13.7 million, powder drinks increased 7.4% to about $7.1 million, and bioactive ingredients climbed 38.5% to about $9.1 million. Looking ahead, management said Yumen phase one is expected to be completed around May 2023; it should add about 30 metric tons of fragrance-compound capacity and about 200% production capacity for that line, while phase two should add 300 metric tons of bioactive ingredients capacity. Management also said FeatherPure is expected to generate approximately $3 million in revenue over the next two years.

CEO Richard Hu emphasized the company’s R&D capability, business model, and expanding product pipeline as the main strategic drivers. He pointed to proprietary health and personal care products, including FeatherPure and a broccoli-based probiotic powder drink, as new growth opportunities, and said the company is optimistic about their revenue potential. He also said management expects two to three new raw-material categories, two to three M&A deals, and broader global expansion over the next year.

The financial commentary focused on price increases, volume growth, and supply-chain effects. Management said higher average selling prices across all three product categories helped offset raw-material inflation and COVID/logistics disruptions, while bioactive ingredients volume grew from 121,000 kilograms to about 154,000 kilograms. The company reported about $1.3 million of government subsidies in fiscal 2022 versus $450,000 in fiscal 2021, and said it closed a January 2023 offering with gross proceeds of $2.2 million to fund Yumen and working capital. On receivables, CFO Zhenchao Li said payment terms are 90 days, the company had not experienced delinquent payments, and it had collected nearly all balances by January, with no bad debt provision.

The main analyst questions focused on whether Yumen could still be completed in May, why overseas sales fell, and whether the higher accounts receivable balance was a concern. Management said it did not foresee further delay on Yumen, that phase one should add about 30 metric tons of fragrance capacity and phase two about 300 metric tons of bioactive ingredients capacity, and that expected revenue uplift from the plant was about 150%. On overseas sales, management blamed Shanghai port congestion and global raw-material shortages, and said it expects overseas sales to pick up in fiscal 2023. On receivables, CFO Li said collections were on schedule and no bad debt provision was needed.